Poly Medicure Q2 FY27: Rev ₹525 Cr

Metric	Value
Revenue	₹525 Cr

📢 Key Event
Q1 FY27 earnings call highlights revenue growth, margin expansion, and export disruption

🔄 What Changed
Consolidated revenue grew 30.3% YoY to ₹525 crores; gross margin improved to 73.4%; EBITDA guidance maintained at 23-25%

🔮 What's Next
Revenue target of INR3,000+ crores by FY26 (15% CAGR); gross margin guidance of 67-69% standalone and 71-72% consolidated for Q2; EBITDA margin expected to reach upper end of 23-25% range

💡 Investor Takeaway
Shareholders should note near-term export headwinds but long-term growth is anchored in margin-accretive acquisitions, new capacity, and structural demand tailwinds in India’s healthcare market.

Poly Medicure reported consolidated revenue of ₹525 crores in Q1 FY27, up 30.3% YoY, with gross margin at 73.4% and EBITDA margin guided at 23-25%. Management highlighted export disruptions in the Middle East, margin resilience from higher-margin acquisitions, and a target of 15% CAGR targeting INR3,000+ crores revenue by FY26. Capex plans include new facilities in Faridabad (Q1 FY27) and Noida (Q1 FY28) to expand orthopedics, infusion, and cardio segments. Gross margins are expected to stay in the 67-69% (standalone) or 71-72% (consolidated) range in Q2, supported by pricing power and product mix. The company emphasized its 399 global patents, diversification away from vascular dependence, and alignment with Ayushman Bharat’s cost-effective device push.

📄 View Original Announcement (PDF)

📊 Stock Analysis — POLYMED ✨ Ask AI About This

About Poly Medicure Limited (POLYMED)

Healthcare · Healthcare Equipment & Supplies · Listed on NSE

Market Cap: ₹15,192.77 Cr P/E: 46.4

View full POLYMED stock details →

📡 Get AI alerts when POLYMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track POLYMED — Free

💡 Ask AI about this filing

"How will Middle East export disruption impact H2 revenue visibility?" "What is the expected timeline for Noida facility commercial contribution?" "How will inorganic growth target of 20% be sustained post-acquisition integration?"

Ask AI Free →

📊 More POLYMED filings

See all POLYMED filings →

🔥 Also filed on 14 August 2026

CEIGALL Ceigall India Limited Financial Results MAHAPEXLTD Maha Rashtra Apex Corporation Limited Corporate Action SAATVIKGL Saatvik Green Energy Limited Financial Results LIBAS Libas Consumer Products Limited Corporate Action GENUSPOWER Genus Power Infrastructures Limited Financial Results LUXIND Lux Industries Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when POLYMED files new disclosures

Track POLYMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.